GlobeNewswire Inc | Feb 16, 2021 08:00AM EST

February 16, 2021

Click here to join the case

LOS ANGELES, Feb. 16, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Bluebird Bio, Inc. ("Bluebird" or "the Company") (NASDAQ: BLUE) investors that acquired securities between May 11, 2020 and November 4, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that Bluebird made misleading and false statements to the market. Bluebird presented insufficient data to support its U.S. Biologics Licensing Application submission for LentiGlobin for sickle cell disease. Bluebird downplayed the risk of disruptions related to the COVID-19 pandemic to its BLA submission schedule for LentiGlobin for SCD, particularly in regard to manufacturing. Bluebirds public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Bluebird.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firms founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.Admitted CA and NY Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com

Attorney Advertising